PPCB’s (NASDAQ:PPCB – Get Free Report) lock-up period will end on Wednesday, February 11th. PPCB had issued 1,000,000 shares in its IPO on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. After the end of PPCB’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Analyst Ratings Changes
Separately, Weiss Ratings assumed coverage on PPCB in a research report on Wednesday, January 14th. They issued a “sell (e-)” rating for the company. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Research Report on PPCB
PPCB Trading Down 3.9%
About PPCB
Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.
Featured Stories
- Five stocks we like better than PPCB
- Your Bank Account Is No Longer Safe
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- New gold price target
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Can Any Expenses Be Deducted From Capital Gains Tax?
Receive News & Ratings for PPCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPCB and related companies with MarketBeat.com's FREE daily email newsletter.
